Pfizer and Excaliard Pharmaceuticals, Inc. have entered into a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing drugs for the treatment of skin fibrosis. Excaliard will receive an upfront payment and related milestone payments. The acquisition is expected to close by the end of the year. Financial terms were not disclosed. Excaliard’s lead product, EXC 001, is an antisense oligonucleotide currently in Phase II deve...